A detailed history of Parkman Healthcare Partners LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 1,025,754 shares of RCUS stock, worth $16.3 Million. This represents 2.21% of its overall portfolio holdings.

Number of Shares
1,025,754
Previous 415,535 146.85%
Holding current value
$16.3 Million
Previous $6.33 Million 147.84%
% of portfolio
2.21%
Previous 0.93%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $8.35 Million - $11 Million
610,219 Added 146.85%
1,025,754 $15.7 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $2.27 Million - $2.88 Million
155,615 Added 59.87%
415,535 $6.33 Million
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $181,756 - $247,326
12,256 Added 4.95%
259,920 $4.91 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $571,513 - $835,354
42,555 Added 20.75%
247,664 $4.73 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $1.5 Million - $2 Million
85,060 Added 70.85%
205,109 $3.68 Million
Q2 2023

Aug 11, 2023

BUY
$16.97 - $22.03 $289,542 - $375,875
17,062 Added 16.57%
120,049 $2.44 Million
Q1 2023

May 12, 2023

BUY
$15.96 - $23.15 $247,810 - $359,450
15,527 Added 17.75%
102,987 $1.88 Million
Q4 2022

Feb 13, 2023

SELL
$19.7 - $35.71 $993,549 - $1.8 Million
-50,434 Reduced 36.57%
87,460 $1.81 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $774,023 - $1 Million
-33,320 Reduced 19.46%
137,894 $3.61 Million
Q2 2022

Aug 12, 2022

BUY
$17.23 - $37.73 $67,076 - $146,882
3,893 Added 2.33%
171,214 $4.34 Million
Q1 2022

May 13, 2022

BUY
$28.92 - $41.83 $1.45 Million - $2.1 Million
50,222 Added 42.89%
167,321 $5.28 Million
Q4 2021

Feb 11, 2022

SELL
$31.38 - $48.47 $3.75 Million - $5.79 Million
-119,538 Reduced 50.52%
117,099 $4.74 Million
Q3 2021

Nov 12, 2021

SELL
$26.93 - $37.68 $269,300 - $376,800
-10,000 Reduced 4.05%
236,637 $8.25 Million
Q2 2021

Aug 13, 2021

SELL
$22.75 - $35.77 $1.58 Million - $2.48 Million
-69,245 Reduced 21.92%
246,637 $6.77 Million
Q1 2021

May 14, 2021

BUY
$26.16 - $41.39 $2.2 Million - $3.48 Million
84,124 Added 36.3%
315,882 $8.87 Million
Q4 2020

Feb 12, 2021

SELL
$17.0 - $32.36 $55,760 - $106,140
-3,280 Reduced 1.4%
231,758 $6.02 Million
Q3 2020

Nov 13, 2020

BUY
$17.14 - $25.47 $1.29 Million - $1.91 Million
75,038 Added 46.9%
235,038 $4.03 Million
Q2 2020

Aug 13, 2020

BUY
$13.97 - $36.56 $2.24 Million - $5.85 Million
160,000 New
160,000 $3.96 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.